Bio-Path Holdings, Inc., a biotechnology company, through its subsidiary, Bio-Path, Inc., develops liposomal drug delivery systems. Its drug delivery technology distributes nucleic acid drugs throughout the human body via intravenous infusion, as well as enables systemic delivery of antisense, small interfering RNA (siRNA), and small molecules for treatment of cancer.